Citius Oncology Completes $9 Million Offering to Boost Oncology Innovations

Citius Oncology Closes $9 Million Offering

Citius Oncology, Inc. (Nasdaq: CTOR), a biopharmaceutical company dedicated to developing oncology-focused therapies, has recently announced the successful completion of a combined registered direct offering and a concurrent private placement. This financial maneuver has allowed the company to raise approximately $9 million in gross proceeds, fervently aimed at fortifying its operations as it continues its mission in critical care innovation.

The offering, which was strategically priced at $1.75 per share—with accompanying warrants to purchase shares at an exercise price of $1.84—encompassed a total of 5,142,858 shares. The issued warrants will become exercisable after six months, providing investors an opportunity to engage with Citius Oncology’s growth potential over the long term. Maxim Group LLC served as the sole placement agent for this offering, facilitating the company's advancement towards its financial goals.

This move follows the filing of a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC) earlier in September 2025, subsequently declared effective. Notably, the offering's structure emphasizes adherence to regulatory requirements, with the company ensuring full compliance through the necessary filings and disclosures.

The raised funds are earmarked to propel Citius Oncology’s lead asset, LYMPHIR, which gained FDA approval in August 2024 for treating adult patients with relapsed or refractory Cutaneous T-cell Lymphoma, a crucial milestone reflecting the company’s dedication to addressing significant medical needs. The projected market for LYMPHIR is estimated to exceed $400 million, marking a significant opportunity within the underserved oncology field.

Citius Oncology boasts solid intellectual property defenses, including orphan drug status and pending patents, enhancing its competitiveness as it looks to introduce LYMPHIR and other candidates into the market. The company's broader aim is to broaden patient access to transformative oncology therapies, ensuring that every innovative solution translates into better health outcomes.

The offering and subsequent deployment of its proceeds are designed to bolster Citius Oncology’s operational capabilities, focusing on efficient product commercialization and enhancing patient care through innovative therapies. With this influx of capital, the company plans to advance its pipeline, including ongoing development for LYMPHIR and future products aimed at treating various oncology indications.

In conclusion, the successful closing of the $9 million offering positions Citius Oncology to accelerate its growth trajectory, reinforcing its commitment to pioneering oncology therapies and addressing critical healthcare challenges facing patients today. The future looks promising as they prepare for the upcoming growth phases and enhance their market presence significantly.

For further inquiries about Citius Oncology or LYMPHIR, stakeholders are encouraged to visit Citius Oncology's website.